South Texas Accelerated Research Therapeutics, Llc
San Antonio, Texas 78229-3307
5 studies enrolling now · 43 studies all time
What they study most
Adamantinomatous Craniopharyngioma, Adenoid Cystic Carcinoma, Advanced Malignancies, Non-small Cell Lung Cancer, Advanced Malignant Solid Tumors, Advanced Non-Central Nervous System (CNS) Malignancies, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Solid Tumors With KRAS G12C Mutations, Any Solid Tumor, Bladder Cancer, Breast Cancer, CRC
Studies at this site
- FOG-001 in Locally Advanced or Metastatic Solid Tumors — Recruiting now
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — Recruiting now
- A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors — Recruiting now
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors — Recruiting now
- Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment — Recruiting now
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations — Running, not enrolling
- Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors — Stopped early
- Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors — Running, not enrolling
- PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors — Stopped early
- A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors — Stopped early
- A Study of PF-06873600 in People With Cancer — Stopped early
- Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer — Completed
- A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors — Stopped early
- Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer — Completed
- Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 — Stopped early
- A Study of ASP1951 in Subjects With Advanced Solid Tumors — Stopped early
- Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone — Completed
- Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma — Stopped early
- A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors — Completed
- Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors — Completed
- MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors — Completed
- Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy — Completed
- A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors — Completed
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors — Completed
- GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma — Stopped early
- Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies — Completed
- Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers — Completed
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors — Stopped early
- Safety Study of MGD009 in B7-H3-expressing Tumors — Stopped early
- A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies — Stopped early
- Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression — Stopped early
- A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors — Completed
- Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies — Stopped early
- A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors — Stopped early
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors — Completed
- A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body — Completed
- A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab — Completed
- A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) — Completed
- A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients — Completed
- A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer — Stopped early
- Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors — Completed
- A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction — Completed